home / stock / shpmy / shpmy news
2023-09-17 08:35:00 ET Summary Shanghai Hasten Biopharma has entered a $325 million agreement for greater China rights to a PCSK9 inhibitor from LIB Therapeutics. Insilico Medicine has out-licensed global rights to a small molecule inhibitor to Exelixis for BRCA-mutated tumors. ...
Summary Sichuan Kelun-Biotech will partner seven preclinical antibody-drug conjugate assets with Merck in a deal that pays Kelun-Biotech $175 million upfront and up to $9.3 billion in milestones - the third ADC deal between the two companies this year. LianBio announced that Pfizer will...
LianBio Launches to Bring US Assets to China; Announces $719 Million of In-Licensings Perceptive Advisors is launching LianBio to bring US biopharma assets to China. A successful fund operator, Perceptive has made investments in 150 public and 80 private biopharmas and has strong connectio...
SHENZHEN and SHANGHAI , August 6, 2020 /PRNewswire/ -- ImmVira Group Company and Shanghai Pharmaceuticals Holding Co., Ltd today announced a clinical collaboration and exclusive license agreement for ImmVira's MVR-T3011 intratumoral oncolytic virus program for the commercialization of n...
SHANGHAI , Sept. 30, 2019 /PRNewswire/ -- Shanghai Pharmaceuticals Holding Co., Ltd. (Shanghai Pharma) (Hong Kong Stock Exchange: 2607) (Shanghai Stock Exchange: 601607) has launched a new stock incentive plan (the Plan) aligned with international standards aimed at retaining an...
SHANGHAI , April 15, 2019 /PRNewswire/ -- Shanghai Pharmaceuticals Holdings Co . Ltd. (Shanghai Pharma or "the Company") (601607.SH ) ( 2067.HK), a major Chinese pharmaceutical group, has unveiled stock option incentive plans in a milestone move designed to accelerate restructuring ...
News, Short Squeeze, Breakout and More Instantly...
Shanghai Pharmaceuticals Holding Co Ltd ADR Repstg Shs H Company Name:
SHPMY Stock Symbol:
OTCMKTS Market:
SHENZHEN and SHANGHAI , August 6, 2020 /PRNewswire/ -- ImmVira Group Company and Shanghai Pharmaceuticals Holding Co., Ltd today announced a clinical collaboration and exclusive license agreement for ImmVira's MVR-T3011 intratumoral oncolytic virus program for the commercialization of n...
SHANGHAI , Sept. 30, 2019 /PRNewswire/ -- Shanghai Pharmaceuticals Holding Co., Ltd. (Shanghai Pharma) (Hong Kong Stock Exchange: 2607) (Shanghai Stock Exchange: 601607) has launched a new stock incentive plan (the Plan) aligned with international standards aimed at retaining an...
SHANGHAI , April 15, 2019 /PRNewswire/ -- Shanghai Pharmaceuticals Holdings Co . Ltd. (Shanghai Pharma or "the Company") (601607.SH ) ( 2067.HK), a major Chinese pharmaceutical group, has unveiled stock option incentive plans in a milestone move designed to accelerate restructuring ...